Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

1.

The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA.

Ladner SK, Miller TJ, King RW.

Antimicrob Agents Chemother. 1998 Aug;42(8):2128-31.

PMID:
9687422
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues.

Ladner SK, Miller TJ, Otto MJ, King RW.

Antivir Chem Chemother. 1998 Jan;9(1):65-72.

PMID:
9875378
[PubMed - indexed for MEDLINE]
3.

Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine.

King RW, Ladner SK, Miller TJ, Zaifert K, Perni RB, Conway SC, Otto MJ.

Antimicrob Agents Chemother. 1998 Dec;42(12):3179-86. Erratum in: Antimicrob Agents Chemother 1999 Mar;43(3):726.

PMID:
9835512
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance.

Fu L, Cheng YC.

Biochem Pharmacol. 1998 May 15;55(10):1567-72.

PMID:
9633992
[PubMed - indexed for MEDLINE]
5.

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.

Melegari M, Scaglioni PP, Wands JR.

Hepatology. 1998 Feb;27(2):628-33.

PMID:
9462667
[PubMed - indexed for MEDLINE]
6.

Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus.

Ling R, Harrison TJ.

J Gen Virol. 1999 Mar;80 ( Pt 3):601-6.

PMID:
10091998
[PubMed - indexed for MEDLINE]
Free Article
9.

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.

Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD.

Hepatology. 1998 Jun;27(6):1670-7.

PMID:
9620341
[PubMed - indexed for MEDLINE]
10.

Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants.

Jardi R, Buti M, Rodriguez-Frias F, Cotrina M, Costa X, Pascual C, Esteban R, Guardia J.

J Virol Methods. 1999 Dec;83(1-2):181-7.

PMID:
10598095
[PubMed - indexed for MEDLINE]
11.

The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.

Paik YH, Han KH, Hong SP, Lee HW, Lee KS, Kim SO, Shin JE, Ahn SH, Chon CY, Moon YM.

Antivir Ther. 2006;11(4):447-55.

PMID:
16856618
[PubMed - indexed for MEDLINE]
12.

Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B.

Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H.

J Med Virol. 1999 Nov;59(3):270-6.

PMID:
10502255
[PubMed - indexed for MEDLINE]
13.

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.

Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, Brown NA.

Lancet. 1997 Jan 4;349(9044):20-2.

PMID:
8988118
[PubMed - indexed for MEDLINE]
14.

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.

Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ.

Antimicrob Agents Chemother. 2002 Aug;46(8):2525-32.

PMID:
12121928
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine.

Tatti KM, Korba BE, Stang HL, Peek S, Gerin JL, Tennant BC, Schinazi RF.

Antiviral Res. 2002 Jul;55(1):141-50.

PMID:
12076758
[PubMed - indexed for MEDLINE]
16.

Antiviral activity of 5'-O-carbonate-2',3'-dideoxy-3'-thiacytidine prodrugs against hepatitis B virus in HepG2 2.2.15 cells.

Gagey D, Ravetti S, Castro EF, Gualdesi MS, BriƱon MC, Campos RH, Cavallaro LV.

Int J Antimicrob Agents. 2010 Dec;36(6):566-9. doi: 10.1016/j.ijantimicag.2010.08.012. Epub 2010 Oct 14.

PMID:
20947311
[PubMed - indexed for MEDLINE]
18.

Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.

Enomoto M, Tamori A, Kohmoto MT, Morikawa H, Habu D, Sakaguchi H, Takeda T, Seki S, Kawada N, Shiomi S, Nishiguchi S.

J Med Virol. 2007 Nov;79(11):1664-70.

PMID:
17854034
[PubMed - indexed for MEDLINE]
19.

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine.

Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ.

Hepatology. 1996 Sep;24(3):711-3.

PMID:
8781347
[PubMed - indexed for MEDLINE]
20.

Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains of Hepatitis B Virus genotype C.

Xu WZ, Fang Y, Li D, Wang Y, Shang QL, Li GQ, Teng X, Gu HX.

World J Gastroenterol. 2008 Jun 21;14(23):3733-8.

PMID:
18595141
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk